Sartorius Stedim Biotech Unveils Unaudited Q1 2024 Results

• Sartorius Stedim Biotech published unaudited first quarter results for 2024 with sales revenue of 667 million euros, a decrease of 8.2 percent compared to the previous year.
• The company's order intake increased by 13.9 percent to 676 million euros, with significant growth in recurring business, but weak demand from China.
• The underlying EBITDA was at 191 million euros, with a resulting margin at 28.6 percent and a net profit of 56 million euros.
• Despite the challenging market environment, the company anticipates business momentum to gradually pick up from quarter to quarter and forecasts sales revenue growth in the mid to high single-digit percentage range for the full year.
• The company's key financial indicators remain at a sound level with equity at 3,867 million euros as of March 31, 2024, and the equity ratio increased to 45.8 percent.
• The company confirms its expectations for the current fiscal year and anticipates a rise in the underlying EBITDA margin to more than 30 percent compared with the previous year's figure of 28.3 percent.

The next important date, Quarterly report, at Sartorius Stedim Biotech is on 18.04.2024.

Sartorius Stedim Biotech

-3,87 %

+1,84 %

-23,16 %

-15,67 %

-16,49 %

-46,79 %

+67,18 %

+404,75 %

ISIN:FR0013154002WKN:A2AJKS

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max